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ABSTRACT 
Background: Plasma total homocysteine (tHcy) has been implicated in the 
development of cardiovascular disease (CVD), but the mechanisms remain unclear. 
Vitamin A (Vit-A) is involved in homocysteine metabolism and we therefore 
explored the potential interaction between plasma tHcy and serum Vit-A in relation to 
incident acute myocardial infarction (AMI). 
Methods: Cox proportional hazards models were used to assess the prospective 
relationships between tHcy and AMI in 2205 patients from Western Norway 
undergoing elective coronary angiography for suspected stable angina pectoris. 
Results are reported as hazard ratio per standard deviation (HR per SD) increase in 
log-transformed tHcy. An interaction term for tHcy × Vit-A was added to multivariate 
models including age, sex, smoking, apolipoprotein B, and estimated glomerular 
filtration rate. 
Results: Geometric mean (geometric standard deviation) age of the participants 
(64.3% men) was 62.3 (1.24) y. Plasma tHcy was higher among participants in the 
upper vs. lower Vit-A tertile. During 7 (2.4) y of follow-up, 15.1% suffered an AMI. 
A significant association of plasma tHcy with AMI in the total study population was 
observed. When we stratified the population according to Vit-A tertiles, plasma tHcy 
was only associated with AMI only in the upper Vit-A tertile (HR per SD: 1.25, 95% 
CI: 1.04-1.53, Pinteraction = 0.03).  
Conclusions: The risk relationship between plasma tHcy and AMI was modified by 
serum concentrations of Vit-A in patients with suspected stable angina pectoris. This 
finding may clarify the relationship between tHcy and CVD. 
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INTRODUCTION 
The non-protein, sulfur-containing amino acid homocysteine is produced by 
intracellular transmethylation reactions where a methyl group is transferred from the 
universal methyl donor S-adenosylmethionine (SAM) to a methyl acceptor1. This 
reaction produces S-adenosylhomocysteine (SAH), which is readily hydrolyzed to 
adenosine and homocysteine in a reversible reaction. In the circulation, homocysteine 
undergoes disulphide exchange reactions forming symmetrical and mixed disulphides, 
which are collectively referred to as total homocysteine (tHcy)2. Elevated plasma 
concentrations of tHcy have been linked to increased risk of cardiovascular disease 
(CVD) in observational studies3, findings that were recently suggested to depend on 
oxidative stress and inflammation4. However, tHcy-lowering treatment with B-
vitamins did not improve prognosis in secondary prevention trials, and the potential 
underlying pathological mechanisms for the risk relationship of tHcy with CVD 
remain unclear5. 
Vitamin A (Vit-A) designates a class of fat-soluble compounds abundant in 
Western diets6. In target cells, retinol is a precursor for the major bioactive retinoid, 
retinoic acid (RA), which is a ligand for nuclear RA receptors. The role of Vit-A in 
CVD development is unclear7, but we have shown that serum Vit-A modified the risk 
association between lipid parameters and acute myocardial infarction in the same core 
population as the current study8. Moreover, synthesis of all-trans-RA is increased in 
some inflammatory conditions9 and is promoted by mediators of oxidative stress and 
inflammation such as oxysterols10. This potentially increased synthesis of all-trans-
RA may have metabolic ramifications to homocysteine. Circulating tHcy has been 
positively associated with Vit-A in an observational study11, and all-trans-RA is a 
potent activator of glycine N-methyltransferase (GNMT), which produces SAH and 
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homocysteine under conditions of excess intracellular SAM12-15. GNMT is not only 
involved in the regulation of intracellular homocysteine concentrations16, but also 
lipid metabolism17 and cellular immune activation18.  
Taken together, the association of plasma tHcy with risk of CVD may be 
modified by Vit-A through several biological mechanisms. However, evidence is 
limited, predominantly experimental and little is known about this relationship in 
humans. The aim of this observational study among more than 2000 patients with 
suspected stable angina pectoris, was to explore whether the relationship of plasma 
tHcy with risk of AMI was modified by serum concentrations of Vit-A.  
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SUBJECTS AND METHODS 
A total of 4164 patients undergoing elective coronary angiography for suspected 
stable angina pectoris at Haukeland (n = 3413) and Stavanger (n = 751) University 
Hospitals, Norway, in the period 2000-2004 were enrolled in this study. In total, 
61.8% (n = 2573) participated in the Western Norway B-Vitamin Intervention Trial 
(WENBIT) (clinicaltrials.gov: NCT00354081) and received either 1) folic acid, 
vitamin B12 and vitamin B6, 2) folic acid and vitamin B12, 3) vitamin B6 or 4) placebo 
19. Subjects with missing data on plasma tHcy or serum Vit-A and those who received 
B-vitamin treatment (n = 1959) in the WENBIT were excluded yielding a total of 
2205 subjects available for the present study. Written informed consent was obtained 
from all participants and the study protocol was in accordance with the principles of 
the Declaration of Helsinki, and approved by the Regional Committee for Medical 
and Health Research Ethics, the Norwegian Medicines Agency, and the Norwegian 
Data Inspectorate.  
 
Baseline data and biochemical analyses 
CVD history and prescription of medications at baseline were self-reported and 
verified by hospital records19. Patients with diabetes were classified by previous 
diagnosis (type 1 or 2), having fasting or non-fasting serum glucose > 7.0 or > 11.1 
mmol/L, respectively, or having baseline glycated hemoglobin > 6.5%. Definitions of 
smoking and severity of coronary artery disease as well as the calculation of 
glomerular filtration rate (eGFR) have been described previously20.  
Blood samples, mostly non-fasting (80%), were collected at baseline. Plasma 
and serum samples were stored at -80°C until analysis. Plasma concentrations of tHcy 
were analyzed using gas chromatography mass spectrometry21, whereas serum Vit-A 
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(as all-trans retinol)22 and neopterin23 by liquid chromatography tandem mass 
spectrometry by BEVITAL AS (www.bevital.no). Serum concentrations of 
apolipoprotein B and C-reactive protein (CRP), and dietary Vit-A intake was 
measured as described previously8, 20. 
 
Follow-up and clinical endpoints 
The participants were followed from baseline to the date of AMI diagnosis, death, or 
through December 31, 2009 (the end of follow-up), whichever came first. AMI cases 
were ascertained via record linkage to national hospital discharge diagnoses obtained 
from the Cardiovascular Disease in Norway project (www.cvdnor.no) through 200924-
26. The primary outcome was hospitalization or death attributed to AMI (coded I21, 
I22, I46.1, R96, and R98 according to the International Statistical Classification of 
Diseases 10th version). If more than one AMI event occurred in a participant during 
the follow-up period, only the first event was considered. An 11-digit personal 




Due to non-normality, continuous variables are presented as geometric means (gM) 
(geometric standard deviation (gSD)). Categorical variables are given as percentages 
(%). Baseline characteristics are presented for the total population and according to 
serum Vit-A tertiles. Trends across Vit-A tertiles were assessed with unadjusted 
ordinary least squares or logistic regression. Skewed variables were log-transformed 
before analyses. Survival analyses were carried out using Cox regression and reported 
as hazard ratios (HRs) (95% confidence intervals (CIs)) per 1 SD log-transformed 
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plasma tHcy in one model containing log-transformed tHcy (continuous), age 
(continuous) and sex (binary), and an additional model including additional 
adjustment for smoking (binary), statin prescription (binary), aspirin prescription 
(binary), fasting status (binary), eGFR (continuous) and apolipoprotein B 
(continuous). To assess the effect-modification by Vit-A, Vit-A (continuous), log-
transformed tHcy (continuous) and their interaction term (Vit-A × tHcy) was added to 
the models. To assess the interaction in the presence of competing risks, we computed 
subdistribution HRs from identical models based on the approach proposed by Fine 
and Gray27. To explore whether the results differed in patients with and without 
significant coronary stenosis, we evaluated the Vit-A × tHcy interaction in patients 
with 1-3 stenotic epicardial vessels as well as patients with no significant stenosis in 
models adjusted for age and sex. The assumption of proportionality was evaluated 
visually by log-log plots and quantitatively by calculating Schoenfeld residuals. To 
assess any non-linear relationships between tHcy and risk of AMI according to Vit-A 
tertiles, we constructed generalized additive model (GAM) dose-response curves 
based on the age and sex-adjusted models in each Vit-A tertile. To visualize the 
interaction of log-transformed tHcy with Vit-A, we constructed an interaction plot. In 
brief, we plotted the HR of log-transformed tHcy against a given range of Vit-A (0-7 
μmol/L), and thus illustrated how the association of log-transformed tHcy with AMI 
changes with increasing concentrations of Vit-A. We considered p-values <0.05 
significant. The statistical basis and R-codes for this procedure has been published28. 
Statistical analyses were carried out using the “base”, "survival" and “cmprsk” 
packages, whereas the GAM plot was created using the “mgcv” package for R 3.0.2 






Baseline characteristics of the total study population and according to Vit-A tertiles 
are presented in Table 1. The total population included a total of 2205 participants of 
which 64.3% were male with a gM (gSD) age of 62.3 (1.24) years. The gM (gSD) 
serum concentration of Vit-A was 2.93 (1.28) μmol/L. Cutoffs for serum Vit-A in the 
tertiles were <2.65, 2.65-3.20 and >3.20 μmol/L in the 1st, 2nd and 3rd tertile, 
respectively. Participants in the upper Vit-A tertile tended to be men, have 
hypertension and higher concentrations of LDL-cholesterol, apolipoprotein B, 
triglycerides, apolipoprotein A1, neopterin and tHcy, whereas CRP and eGFR tended 
to be lower. No trend for Vit-A intake was observed across serum Vit-A tertiles. 
 
Association between plasma tHcy and AMI  
During gM (gSD) follow-up time of 7.0 (2.4) y, 333 (15.1%) patients were diagnosed 
with AMI. As expected, there was a positive risk relationship between plasma tHcy 
and incident AMI; however the association was somewhat attenuated in the 
multivariate model (Table 2). 
 
Interaction with Vit-A 
As presented in Table 3, we found a significant interaction between tHcy and Vit-A 
in relation to AMI in both models. We constructed GAM plots to assess non-linearity 
between tHcy and AMI in each Vit-A (Figure 1). As can be seen from Figure 1, we 
found no associations between tHcy and AMI in the 1st and 2nd Vit-A tertiles; however 
a positive association was seen in the 3rd Vit-A tertile. This is further illustrated in 
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Figure 2, which shows that the risk relationship of AMI associated with tHcy 
increase in a fully adjusted model when Vit-A concentrations exceed ~3 μmol/L.  
 
Competing risks analysis 
In total, 505 patients died of which 274 (54.3 %) due to non-coronary causes. Based 
on this finding, we calculated subdistribution HRs for getting an AMI in the presence 
of non-cardiovascular mortality. The association of tHcy with AMI was generally 
unchanged in all multivariate models including the upper tertile of Vit-A 
(Subdistribution HR: 1.24, 95% CI: 1.04-1.49, p for interaction = 0.03).  
 
Interaction with Vit-A in patients with and without significant stenosis 
We stratified the population according to the prevalence of significant coronary artery 
disease to evaluate whether the interaction between tHcy and Vit-A differed in the 
two groups. In patients with at least one significant stenosis (n = 1380), 286 (21%) 
events occurred, whereas 47 events (5.6%) occurred in patients without significant 
stenosis (n = 825). Risk estimates and confidence intervals are presented in Table 4. 
There was a significant interaction between tHcy and Vit-A in relation to AMI in 






In this prospective study among more than 2000 patients with stable angina pectoris, 
we showed that plasma tHcy was higher in patients with elevated systemic Vit-A 
concentrations and that the association between tHcy and risk of AMI was primarily 
confined to patients in the highest tertile of serum Vit-A. 
 
Homocysteine and Vit-A 
Our findings are of interest considering our previously published results indicating 
effect modification by serum Vit-A on the association between traditional lipid 
parameters and incident CVD8. We also demonstrated a positive association between 
baseline plasma tHcy and serum Vit-A, which is in line with findings among 
overweight but otherwise healthy individuals11. Positive associations for Vit-A29, its 
transport protein retinol-binding protein 430, and cardiovascular endpoints has been 
reported from some prospective cohorts, but no interaction with other common risk 
factors have been reported. To our knowledge, epidemiological evidence on the 
interaction between tHcy and Vit-A with respect to incident AMI or CVD in general 
has not been assessed previously that we know of. 
 
Potential mechanisms 
Experimental data on the interaction between homocysteine and Vit-A are limited, but 
possible mechanisms may include inflammation and lipid metabolism. Inflammatory 
conditions such as non-alcoholic fatty liver disease increase hepatic expression of 
genes involved in all-trans-RA synthesis9. Inflammatory markers such as oxysterols 
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stimulate synthesis of all-trans-RA in the liver10, which in turn may affect 
homocysteine through induction of GNMT13, 15, 31. Notably, GNMT plays a role in the 
production of interferon-γ, which drives synthesis of the macrophage-specific 
inflammatory marker neopterin18, 32. This pteridine has been related to risk of major 
cardiovascular events in humans32, and potentiated tHcy-mediated risk of CVD in the 
same core population as the present study4. Neopterin was higher among patients with 
elevated Vit-A in the present study, and the tHcy-associated risk we observed in our 
study may reflect pro-inflammatory conditions that contribute to atherosclerosis. In 
contrast, CRP, which unlike neopterin is produced in the liver as part of the acute 
phase response33 and is associated with aspects of CVD risk34 and complications35, 
tended to be lower among patients with elevated Vit-A. Hence, the interaction 
between Vit-A and tHcy and the potential link with inflammation seems to relate to 
specific components of immune activation. This hypothesis needs further exploration 
in future studies. 
Accumulation of cholesterol is crucial for atherosclerotic plaque progression 
and leads to foam cell formation from endothelial-derived smooth muscle like cells36, 
and may relate to impaired reverse cholesterol transport to high-density lipoprotein 
(HDL)37. We recently showed that low concentrations of apolipoprotein A1 (apoA1), 
the major protein constituent of HDL, was associated with excess risk of 
cardiovascular events in patients with elevated Vit-A concentrations8. Homocysteine, 
partially produced by GNMT in the liver, accelerates hepatic clearance of HDL38 and 
inhibits synthesis of apoA1 in the liver of mice and men with coronary heart disease39. 
Thus, homocysteine may exert detrimental effects on reverse cholesterol transport 
from atherosclerotic plaques and the dynamic exchange of cholesterol between HDL 
and low-density lipoprotein particles in the circulation by limiting HDL availability. 
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However, this proposed mechanism is complicated by the demonstration that GNMT 
ablation in macrophages impaired reverse cholesterol transport37, indicating that the 
outlined mechanism involving Vit-A and GNMT may be tissue-dependent.  
 Taken together, we speculate that elevated Vit-A activity modifies the tHcy-
associated risk of CVD. Notably, tHcy-associated risk among these patients may 
reflect immune activation and disrupted lipid metabolism. However, well-defined 
mechanistic studies are needed to explore this potential biological interaction in 
greater detail, and possibly with regards to different tissues.  
  
Relevance 
Recent dietary intake of Vit-A is not likely to affect the observed relationship as it 
does not affect serum Vit-A concentrations except in individuals with extreme excess 
or deficient intake40. Thus, the high circulating Vit-A levels may reflect metabolic 
disturbances as has been shown in animal models41. Adjustment for important 
confounders such as kidney function, which is a determinant of both serum Vit-A42 
and plasma tHcy43, did not attenuate the interaction significantly. Although the 
interaction between tHcy and Vit-A appeared to be independent of other known risk 
factors, it is essential to replicate the findings in other studies.  
In an attempt to explore whether the interaction differed according to the 
prevalence of coronary artery disease we stratified our patients based on the presence 
of significant coronary stenosis. We observed a significant interaction between tHcy 
and Vit-A in patients with 1-3 stenotic epicardial vessels, but not in patients without 
significant stenosis. These observations indicate that the interaction was confined to 
patients with more severe disease; however, the statistical power to detect the 
interaction in patients without coronary stenosis was weak (47 AMI events). These 
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subgroup observations are exploratory but highlight the necessity of investigating this 
interaction in large and initially healthy cohorts.  
 
Strengths and limitations 
This study included a large and well-characterized population with established CVD. 
Given the high levels of circulating Vit-A compared with other populations29, 44, this 
cohort may have been particularly suitable for the current study objective. In contrast, 
the results reported in this study may not be generalizable to the general population 
because the patients were at increased CVD risk upon recruitment. 
The majority of samples were drawn from non-fasting subjects, and tHcy has 
been found to be modestly increased following food intake45-47, but adjustment for 
fasting state in the multivariate models did not alter the risk estimates significantly. 
The findings and proposed mechanisms are further complicated by the possibility that 
Vit-A concentrations do not necessarily reflect biological activity in tissues. Finally, 
as this study is of observational nature, it does not allow for causal inference due to 
the possibility of residual confounding such as long-term use of high-dose 
supplements40, 48.  
 
Conclusions 
The results from the present exploratory study suggest that the association of 
circulating concentrations of tHcy with incident AMI is confined to patients with 
elevated serum concentrations of Vit-A. These findings may shed light on the hitherto 
unclear relationship between tHcy and CVD. We speculate that tHcy-associated risk 
may reflect disturbed lipid metabolism and thus experimental and mechanistic studies 
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Table 1: Baseline characteristics for the total study population (n = 2205) with suspected stable angina pectoris 
 
Total study population 1st Vit-A tertile 2nd  3rd p for trend1 
 
- < 2.65 μmol/L 2.65-3.20 μmol/L > 3.20 μmol/L 
  (n = 2205) (n = 728) (n = 727) (n = 750)  
Age, y 62.3 (1.24) 61.4 (1.20) 60.3 (1.21) 60.4 (1.20) 0.229 
Male sex, n (%) 1418 (64.3) 438 (60.2) 469 (64.5) 511 (68.1) 0.001 
Fasting, n (%) 418 (19.8) 150 (21.6) 137 (19.6) 131 (18.2) 0.155 
Smoking, n (%) 689 (31.2) 233 (32.0) 235 (32.3) 221 (29.5) 0.323 
1-3 stenotic vessels, n (%) 1380 (62.6) 490 (67.3) 454 (62.4) 436 (58.1) 0.005 
Diabetes mellitus, n (%) 274 (12.4) 106 (14.6) 75 (10.3) 93 (12.4) 0.157 
Hypertension, n (%) 1030 (46.7) 330 (45.3) 317 (43.6) 383 (51.1) 0.025 
LVEF < 60, n (%) 1784 (80.9) 593 (81.5) 592 (81.4) 599 (79.9) 0.327 
Previous AMI, n (%) 817 (37.1) 273 (37.5) 264 (36.3) 280 (37.3) 0.958 
ApoB, g/L 0.89 (1.31) 0.86 (1.30) 0.89 (1.30) 0.93 (1.31) <0.001 
ApoA1, g/L 1.33 (1.22) 1.29 (1.23) 1.33 (1.21) 1.37 (1.22) <0.001 
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LDL-C, mmol/L 2.97 (1.39) 2.89 (1.40) 2.98 (1.38) 3.03 (1.39) 0.001 
HDL-C, mmol/L 1.26 (1.34) 1.25 (1.35) 1.27 (1.33) 1.27 (1.32) 0.703 
Triglycerides, mmol/L 1.51 (1.67) 1.3 (1.61) 1.46 (1.62) 1.79 (1.7) <0.001 
CRP, mg/mL 1.97 (2.99) 2.43 (3.27) 1.85 (2.93) 1.71 (2.7) <0.001 
eGFR, ml/min per 1.73 m2 83.0 (1.34) 88.5 (1.20) 85.7 (1.21) 75.6 (1.51) <0.001 
Total homocysteine, μmol/L 11.0 (1.4) 10.4 (1.36) 10.7 (1.36) 11.8 (1.44) <0.001 
Neopterin, nmol/L 8.94 (1.51) 8.45 (1.44) 8.65 (1.42) 9.76 (1.64) <0.001 
Retinol intake, RAE/d 1576 (1.83) 1548 (1.73) 1584 (1.91) 1618 (1.91) 0.526 
Medications at discharge, n (%)      
Statins 1605 (72.8) 526 (72.3) 525 (72.2) 554 (73.9) 0.286 
Aspirin 1642 (74.5) 542 (74.5) 540 (74.3) 560 (74.7) 0.621 
Beta-blockers 1479 (67.1) 490 (67.3) 478 (65.7) 511 (68.1) 0.601 
1P-values for trends across tertiles of vitamin A were calculated by linear regression for continuous variables and logistic regression for 
categorical variables. Abbreviations: LVEF, left ventricular ejection fraction; AMI, acute myocardial infarction; ApoB, apolipoprotein B; 
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ApoA1, apolipoprotein A1; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol; CRP, C-reactive 
protein; eGFR, estimated glomerular filtration rate. Values are geometric mean (geometric standard deviation) for continuous variables and n 
(%) for categorical variables.  
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TABLE 2 
tHcy-related risk of AMI in the total population1 
 
        
Total population (No of events, 333/2205) 
HR per SD (95% 
CI) 
P -value 
   Model 12 1.22 (1.10-1.35) < 0.01 
Model 23 1.12 (0.99-1.26) 0.07 
1 Risk as hazard ratios (95% confidence intervals (CIs) per 1 SD log-transformed 
plasma tHcy computed by Cox proportional hazards model 
2 Adjusted for age and gender 
3 Adjusted for age, gender, smoking, estimated glomerular filtration rate, statin 








tHcy-related risk of AMI across tertiles of vitamin A1 
  Tertiles of serum vitamin A2  
P for interaction 
  1st 2nd 3rd  
No. of events/n  117/728 108/727 108/750   
       
Model 13  1.10 (0.90-1.34) 1.11 (0.90-1.38) 1.41 (1.21-1.64)  <0.001 
Model 24  1.08 (0.88-1.33) 1.09 (0.86-1.38) 1.25 (1.04-1.52)  0.03 
1 Risk as hazard ratios (95% confidence intervals (CIs) per 1 SD log-transformed plasma tHcy, computed by Cox proportional hazards 
model 
2 Cut-offs for serum Vit-A tertiles were <2.65, 2.65-3.20 and >3.20 μmol/L 
3 Adjusted for age and gender 




tHcy-related risk of AMI across tertiles of vitamin A in patients with and without significant coronary stenosis at baseline 
angiography1 
  Tertiles of serum vitamin A2,3  
P for interaction 
  1st 2nd 3rd  
Stenosis       
No. of events/n  92/461 101/459 93/460   
  1.08 (0.88-1.34) 1.15 (0.93-1.42) 1.47 (1.26-1.71)  0.02 
No stenosis       
No. of events/n  19/276 13/274 15/275   
  1.04 (0.63-1.71) 0.73 (0.36-1.48) 1.04 (0.58-1.56)  0.56 
1 Risk as hazard ratios (95% confidence intervals per 1 SD log-transformed plasma tHcy, computed by Cox proportional hazards 
model adjusted for age and sex 
2 Cut-offs for serum Vit-A tertiles were <2.62, 2.62-3.15 and >3.15 μmol/L for patients with coronary stenosis 
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3 Cut-offs for serum Vit-A tertiles were <2.73, 2.73-3.30 and >3.30 μmol/L for patients without coronary stenosis 
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Figure 1: The dose-response relationship between log-transformed total 
homocysteine and acute myocardial infarctions in the 1st (A), 2nd (B) and 3rd (C) 
tertile of vitamin A computed by generalized additive models. Data are adjusted for 
age and sex. The blue shaded areas around the curve represent the 95% confidence 
intervals. Kernel distribution plots show the distribution of total homocysteine.  
 
Figure 2: Illustration of the interaction between serum vitamin A and log-transformed 
total homocysteine on the continuous scale. The blue shaded areas around the curve 
represent the 95% confidence intervals. HR per SD, hazard ratio per standard 
deviation; tHcy, total homocysteine 
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